Featured Research

from universities, journals, and other organizations

Antibodies to immune cells protect eyes in Pseudomonas infection

Date:
October 22, 2012
Source:
American Society for Microbiology
Summary:
Contact lenses, particularly the extended wear variety, render wearers vulnerable to eye infections from Pseudomonas aeruginosa. These infections can cause severe damage, including blindness. Treating the eye with antibodies to the inflammatory immune compound interleukin-17 (IL-17) reduced eye damage and the number of bacteria in a mouse model.

Contact lenses, particularly the extended wear variety, render wearers vulnerable to eye infections from Pseudomonas aeruginosa. These infections can cause severe damage, including blindness. Treating the eye with antibodies to the inflammatory immune compound interleukin-17 (IL-17) reduced eye damage and the number of bacteria in a mouse model. The research is published in the October Infection and Immunology.

The onslaught of Pseudomonas infection of the eye is often swift, and is aggravated by the bacterium's resistance to antibiotics. "Pseudomonas is everywhere in the environment, and can be unwittingly introduced into the lens cleaning solution, or directly onto the contact lens, so everyone who uses contact lenses is at risk," says principal investigator Gregory P. Priebe of Brigham and Women's Hospital, Boston, and Boston Children's Hospital.

Immune cells known as neutrophils are a major cause of the eye damage that ensues from Pseudomonas infection. IL-17 is involved in attracting neutrophils to the infected tissues. They are the vanguard of immune attack, arriving at a site of infection within an hour, trapping, and ingesting pathogens. In their pathogen-killing function, they also release noxious substances, notably elastase, an enzyme that can chew up tissues, and superoxide, which is converted into hypochlorous acid, more commonly known as chlorine bleach. Thus, the ensuing eye damage is not surprising.

Nonetheless, the strategy of blocking these pathogen killing cells risked reducing the immune system's bacteria-killing function, says Priebe. "Surprisingly, just the opposite was seen: blocking IL-17 with antibodies led both to fewer neutrophils in the eye, and to fewer bacteria," says Priebe. Thus, he says, the research may lead to effective treatments.

"We thought that blocking IL-17 infection might worsen eye infections, but found just the opposite,' says Priebe . "Interestingly, this is a common pattern in eye infections. The body's responses that make the damage worse are often the same things needed to limit infections in other tissues, such as the lung."


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. S. Zaidi, T. Zaidi, G. B. Pier, G. P. Priebe. Topical Neutralization of Interleukin-17 during Experimental Pseudomonas aeruginosa Corneal Infection Promotes Bacterial Clearance and Reduces Pathology. Infection and Immunity, 2012; 80 (10): 3706 DOI: 10.1128/IAI.00249-12

Cite This Page:

American Society for Microbiology. "Antibodies to immune cells protect eyes in Pseudomonas infection." ScienceDaily. ScienceDaily, 22 October 2012. <www.sciencedaily.com/releases/2012/10/121022194457.htm>.
American Society for Microbiology. (2012, October 22). Antibodies to immune cells protect eyes in Pseudomonas infection. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2012/10/121022194457.htm
American Society for Microbiology. "Antibodies to immune cells protect eyes in Pseudomonas infection." ScienceDaily. www.sciencedaily.com/releases/2012/10/121022194457.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins